Ultime notizie per Fortis (NYSE:FTS) Azioni

Fortis

Fortis owns and operates eight utility transmission and distribution subsidiaries in Canada and the United States, serving more than 3.4 million electricity and gas customers. The company has smaller stakes in electricity generation and several Caribbean utilities. Subsidiary ITC operates electric transmission in seven US states, with more than 16,000 miles of high-voltage transmission lines in operation.

Fortis Inc

Franklin Short Duration U.S. Government ETF

First Trust Senior Loan Fund

First Trust Enhanced Short Maturity ETF

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

BJDX

SMST

LIFW

SMCX

LIFWW

Numinus Wellness Inc. (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/NUMIF#OTCQX">NUMIF</a>), a leader in <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">psychedelic-assisted mental health care</a>, has <a href="https://www.investors.numinus.com/news/news-details/2024/Numinus-Wellness-Announces-Sale-of-Clinics-and-Unique-Data-Partnership-to-Increase-Access-to-Mental-Health-Care/default.aspx">announced</a> a definitive agreement with Stella, an interventional psychiatry practice, to sell its five wellness clinics in Utah for a total of $3.53 million. The transaction, expected to close by November 30, marks a strategic shift for Numinus, as it pivots towards <a href="https://www.benzinga.com/markets/cannabis/24/09/40845569/mdma-therapy-for-ptsd-faces-fda-delay-are-there-other-ways-forward">developing technology-driven solutions</a> aimed at enhancing the efficiency of mental health care providers.
<h3 class="wp-block-heading">Tech Partnership To Redefine Mental Health Clinics</h3>
In addition to the sale, Numinus and Stella will collaborate on a data-sharing initiative to launch an innovative clinic management platform. By leveraging operational insights from Stella's 12 clinics, Numinus plans to develop a software solution designed to streamline clinic operations, enhance patient outcomes and support insurance reimbursement processes.
"This transaction marks an exciting new chapter in Numinus' strategy to reshape behavioral health care," said Payton Nyquvest, founder and CEO of Numinus. "Leveraging our expertise in patient care, we're now accelerating our mission by focusing on cutting-edge technology solutions. Through our partnership with Stella, we gain unprecedented access to operational data that will enable us to develop a SaaS (software as a service) solution to redefine how clinics operate."
<h3 class="wp-block-heading">Stella Takes Over Utah Operations</h3>
Stella, known for its focus on treating PTSD, anxiety and depression through biological modalities, will assume control of Numinus' Utah clinics. The acquisition includes an upfront payment of $2.08 million, followed by $750,000 in installments throughout 2025, and up to $700,000 in deferred compensation.
"Stella's expansion into Utah brings additional life-changing treatments to the community while supporting Numinus' broader tech initiatives," stated Michael Gershenzon, co-founder and CEO of Stella. "This partnership reflects our commitment to improving behavioral health systems and processes, ultimately enhancing patient care."
<h3 class="wp-block-heading">An Asset-Light Business Model With Enhanced Focus</h3>
With the sale of its clinics, Numinus will shift towards an asset-light model, focusing on its business units like Cedar Clinical Research and the Numinus Network. The strategy aims to integrate clinical research, practitioner training and technology solutions, supporting mental health providers worldwide. The move is part of a broader effort to ease the operational burdens faced by healthcare professionals, particularly as demand for treatments like <a href="https://www.benzinga.com/topic/ketamine-therapy">ketamine</a> and Spravato continues to rise.
"Stella will bolster our clinical solutions offering, leveraging their deep expertise in patient care," Nyquvest added. "We expect strong demand for our Numinus Network Solutions as mental health practitioners navigate growing requests for care."
Cover image made with AI

Cannabis

News

Psychedelics

NUMIF

Numinus Wellness Sells US Clinics, Partners With Stella For Tech-Driven Mental Health Solutions

President-elect Donald Trump has chosen former Representative Doug Collins (R-GA) to lead the <a href="https://www.benzinga.com/cannabis">U.S. Department of Veterans Affairs (VA). </a>
The decision has sparked discussions about how the agency might handle medical cannabis issues, given his inconsistent track record on the issue, as <a href="https://www.marijuanamoment.net/trumps-pick-to-lead-va-voted-against-letting-agency-doctors-recommend-medical-marijuana-to-veterans-before-he-adopted-a-pro-reform-position/">reported</a> Marijuana Moment.
<h3 class="wp-block-heading">Collins' Record On Cannabis</h3>
During his time in Congress, Collins opposed efforts to expand access to medical cannabis for veterans. Between 2014 and 2016, he voted against three proposals that would have allowed VA doctors to recommend cannabis to their patients.
See Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/42018478/trumps-cabinet-choices-will-his-administration-support-or-restrict-cannabis">Trump&#8217;s Cabinet Choices: Will His Administration Support Or Restrict Cannabis?</a>
Collins' views began to shift in 2019. He supported the STATES Act, which would protect state marijuana programs from federal interference, and co-signed a letter with Rep. Matt Gaetz (R-FL), urging Congress to take action on cannabis policy. 
"We believe this Committee and this Congress must act to clarify the rights and responsibilities, relative to cannabis, of individuals, physicians, businesses, medical patients, and law enforcement officials," they wrote.
Later that year, Collins backed a bipartisan bill to protect banks that serve marijuana businesses in states where it is legal. However, he did not take part in a 2020 vote on federal cannabis legalization.
<h3 class="wp-block-heading">Collins' Stance On Psychedelics</h3>
When it comes to psychedelics, there isn't much known about Collins's stance. However, his shifting views on cannabis policy hint that he could be open to exploring different approaches.
<h3 class="wp-block-heading">Cannabis At The VA</h3>
VA policy has long prohibited its doctors from recommending cannabis, citing marijuana's classification as a Schedule I controlled substance under federal law. This stance has remained consistent across both Republican and Democratic administrations, despite growing support for change in Congress.
Recent efforts to address this issue include a Senate Appropriations Committee request for the VA to explore cannabis as an alternative to opioids. Lawmakers have also introduced measures that would allow VA doctors to recommend cannabis in states where it is legal. These efforts have gained bipartisan support, but none have yet become law.
Veterans service organizations have pushed for further reforms, including expanded research into the potential benefits of cannabis. Last year, a Senate committee approved a bill to study cannabis for veterans with certain medical conditions, but it failed to advance to a floor vote.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/11/42017583/trumps-go-wild-on-health-plan-puts-rfk-jr-in-charge-what-it-means-for-cannabis-and-psychedelics-reform">Trump&#8217;s &#8216;Go Wild On Health&#8217; Plan Puts RFK Jr. In Charge: What It Means For Cannabis And Psychedelics Reform</a></li>
</ul>
Cover image made with AI.

Government

Politics

Markets

Trump-Appointed Doug Collins To Lead VA: What's Next For Cannabis and Psychedelics In Veterans' Healthcare?

Chardan Capital analyst Daniil Gataulin maintains Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) with a Buy and maintains $6 price target.

Price Target

Analyst Ratings

CLSD

Chardan Capital Maintains Buy on Clearside Biomedical, Maintains $6 Price Target

Chardan Capital analyst Daniil Gataulin maintains Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) with a Buy and maintains $11 price target.

CGTX

Chardan Capital Maintains Buy on Cognition Therapeutics, Maintains $11 Price Target

Telsey Advisory Group analyst Cristina Fernandez maintains Williams-Sonoma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) with a Outperform and maintains $165 price target.

Telsey Advisory Group Maintains Outperform on Williams-Sonoma, Maintains $165 Price Target

– Approval based on positive data from the AUGMENT-101 clinical trial, in which Revuforj delivered robust and durable rates of remission in R/R acute leukemia patients with a KMT2A translocation –
– Syndax to host conference call today at 6:00 p.m. ET –
WALTHAM, Mass., Nov. 15, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) today announced that the U.S. Food and Drug Administration (FDA) has approved Revuforj&#xAE; (revumenib) as the first and only menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients one year and older. The FDA previously granted Breakthrough Therapy and Fast Track designations as well as Priority Review for Revuforj. The New Drug Application (NDA) received approval through the FDA's Real Time Oncology Review (RTOR) program.

Biotech

General

SNDX

Syndax Announces FDA Approval Of Revuforj, The First And Only Menin Inhibitor To Treat Adult And Pediatric Patients With Relapsed Or Refractory Acute Leukemia With A KMT2A Translocation

IT Tech Packaging (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ITP#AMEX">ITP</a>) reported quarterly losses of $(0.20) per share. This is unchanged from the same period last year. The company reported $25.08 million in sales this quarter. This is a 59.03 percent increase over sales of $15.77 million the same period last year.

Earnings

IT Tech Packaging Q3 EPS $(0.20), Same YoY, Sales $25.08M Up From $15.77M YoY

RumbleOn, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBL#NASDAQ">RMBL</a>) (the "Company" or "RumbleOn") announced today that the close of business (4:00 p.m. Central Time) on November 25, 2024 has been fixed as the record date (the "Record Date") for its previously announced proposed $10.0 million registered equity rights offering (the "Rights Offering"), which was announced in a Form 8-K filed with the U.S. Securities and Exchange Commission ("SEC") on November 12, 2024.

Offerings

RMBL

RumbleOn Announces That The Close Of Business On November 25, 2024 Has Been Fixed As The Record Date For Its Previously Announced Proposed $10M Registered Equity Rights Offering

Telsey Advisory Group analyst Dana Telsey maintains European Wax Center (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWCZ#NASDAQ">EWCZ</a>) with a Outperform and maintains $8 price target.

EWCZ

Telsey Advisory Group Maintains Outperform on European Wax Center, Maintains $8 Price Target

<a href="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241115-1475367/1475367_4rcm.pdf" title="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241115-1475367/1475367_4rcm.pdf">https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241115-1475367/1475367_4rcm.pdf</a>

FOUR

Shift4 Payments Will Replace R1 RCM In The S&P Midcap 400 Effective Prior To The Opening Of Trading On Wednesday, November 20

China Green Agriculture, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CGA#NYSE">CGA</a>) has changed its name to Enlightify Inc., effective November 25, 2024. Its ticker symbol will change to ENFY effective November 25, 2024, and it is expected to begin trading under that symbol on November 26, 2024. The Company mainly produces and distributes humic acid-based compound fertilizers, other varieties of compound fertilizers and agricultural products through its subsidiaries in China.

China Green Agriculture Changes Name to Enlightify Inc.; Its Ticker Symbol Will Change To 'ENFY' Effective November 25, 2024, And It Is Expected To Begin Trading Under That Symbol On November 26, 2024

Alpha Cognition (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOG#NASDAQ">ACOG</a>) reported quarterly losses of $(0.31) per share. This is a 63.1 percent increase over losses of $(0.84) per share from the same period last year.

ACOG

Alpha Cognition Q2 EPS $(0.31) Up From $(0.84) YoY

D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) with a Buy and maintains $31 price target.

NRXP

D. Boral Capital Maintains Buy on NRX Pharmaceuticals, Maintains $31 Price Target

D. Boral Capital analyst Jason Kolbert maintains VolitionRX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) with a Buy and maintains $5 price target.

VNRX

D. Boral Capital Maintains Buy on VolitionRX, Maintains $5 Price Target

"Our strong third quarter results reflect the growth of our utilities as they continue to execute their capital programs," said David Hutchens, Pre...

Fortis reports Q3 adjusted EPS C$0.85 vs. C$0.84 last year

Fortis, Inc. (FTS) Q3 2024 Earnings Call Transcript

Raymond James analyst Theo Genzebu downgraded Fortis (FTS) to Market Perform from Outperform with an unchanged price target of C$61. Published firs...

Fortis downgraded to Market Perform from Outperform at Raymond James

Fortis (FTS – Research Report), the Utilities sector company, was revisited by a Wall Street analyst yesterday. Analyst Ross Fowler from Bank of Am...

Fortis's Sell Rating: Regulatory Challenges and Below-Average EPS Growth Overshadow Positive Q3'24 Earnings

Wells Fargo analyst Neil Kalton maintained a Hold rating on Fortis (FTS – Research Report) today and set a price target of C$63.00. The company's s...

Wells Fargo Reaffirms Their Hold Rating on Fortis (FTS)

Raymond James last night downgraded Fortis (FTS) to Market Perform from Outperform with an unchanged price target of C$61 following the "solid" Q3 ...

Fortis downgraded to Market Perform on valuation at Raymond James

In a report released today, Mark Jarvi from CIBC maintained a Hold rating on Fortis (FTS – Research Report), with a price target of C$63.00. The co...

CIBC Sticks to Its Hold Rating for Fortis (FTS)

National Bank analyst Patrick Kenny raised the firm's price target on Fortis (FTS) to C$63 from C$62 and keeps a Sector Perform rating on the share...

Fortis price target raised to C$63 from C$62 at National Bank

Utility companies are positioned for long-term growth through clean energy investments as the world shifts towards renewable energy and infrastructure modernization. With rising demand, investors might consider stable utility stocks like Duke Energy (DUK), Engie (ENGIY), and Fortis (FTS), which offer high dividends. Read on... Utilities are experiencing rising demand from AI infrastructure, data centers, and EV charging, driving steady revenue growth. The sector also benefits from the shift to cleaner energy, which supports long-term growth potential. For investors seeking stability, utility stocks like Duke Energy Corporation (<a href="https://stocknews.com/stock/DUK/">DUK</a>), Engie SA (<a href="https://stocknews.com/stock/ENGIY/">ENGIY</a>), and Fortis Inc. (<a href="https://stocknews.com/stock/FTS/">FTS</a>) offer reliable dividends and promising dividend growth.
The utility sector is particularly promising and stable, supported by rising electricity demand from industrial growth and electric vehicles this year. Utilities play an essential role in sustaining critical tech sectors, providing steady demand and a defensive position against economic fluctuations. As a result, in the U.S., electricity demand is projected to grow by 3% in 2024 and by <a href="https://www.iea.org/reports/electricity-mid-year-update-july-2024/executive-summary">1.9% in 2025</a>.
As utilities transition from fossil fuels, they can achieve more stable costs and improved profitability by avoiding price volatility. Investments in nuclear, renewable energy, and methane reduction position utilities as leaders in clean, stable energy, while gas liquefaction supports the transition to lower-emission fuels. The global utilities market is projected to grow at <a href="https://www.researchandmarkets.com/report/utilities">6.8% annually</a>, reaching $8.31 trillion by 2027.
On top of it, anticipated interest rate cuts are likely to ease capital costs, benefiting utility companies reliant on substantial infrastructure spending. With promising local regulatory changes, the sector's outlook remains strong. Investors' interest in utility stocks is evident from the SPDR Select Sector Fund – Utilities' (<a href="https://stocknews.com/stock/XLU/">XLU</a>) 33.9% returns over the past year.
Considering these conducive trends, let's analyze the fundamental aspects of the three utility picks.
Duke Energy Corporation (<a href="https://stocknews.com/stock/DUK/">DUK</a>)
DUK and its subsidiaries operate as an energy company in the United States. It operates through two segments: Electric Utilities and Infrastructure (EU&amp;I), and Gas Utilities and Infrastructure (GU&amp;I).
On October 7, 2024, DUK declared a quarterly cash dividend of $1.05 per share on its common stock and $359.38 per share on its Series A preferred stock, both payable on December 16, 2024, to shareholders of record by November 15, 2024.
In terms of the trailing-12-month <a href="https://www.investopedia.com/terms/g/gross_profit_margin.asp">gross profit margin</a>, DUK's 49.86% is 11.3% higher than the 44.79% industry average. Likewise, its 42.39% trailing-12-month Capex / Sales is 25.5% higher than the 33.77% industry average. Furthermore, the stock's 47.63% trailing-12-month EBITDA margin is 30.2% higher than the 36.58% industry average.
DUK has paid dividends for 17 consecutive years. Its annual dividend is $4.18, which translates to a yield of 3.63% at the current share price. Its four-year average dividend yield is 4.01%. Moreover, the company's dividend payouts have increased at a CAGR of 2% over the past three years.
DUK's total operating revenues for the second quarter that ended June 30, 2024, increased 9% year-over-year to $7.17 billion. Its operating income rose 19.4% over the year-ago value to $1.71 billion. Also, net earnings and adjusted EPS stood at $921 million and $1.18, reflecting increases of 29% and 29.7% year-over-year, respectively.
Street expects DUK's EPS for the quarter ending December 31, 2024, to increase 7.7% year-over-year to $1.63. Its revenue for the quarter ended September 30, 2024, is expected to grow 1.3% year-over-year to $8.10 billion. It surpassed the Street EPS estimates in three of the trailing four quarters.
Over the past year, the stock has gained 29.7% to close the last trading session at $115.27. Its 60-month beta is 0.46.
DUK's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect strong prospects. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.
DUK is ranked #13 out of 59 stocks in the <a href="https://stocknews.com/category/utilities-domestic/">Utilities – Domestic</a> industry. It has a B grade for Growth, Momentum, and Stability. <a href="https://stocknews.com/stock/DUK/">Click here</a> to see DUK's ratings for Value, Sentiment, and Quality.
Engie SA (<a href="https://stocknews.com/stock/ENGIY/">ENGIY</a>)
Headquartered in Courbevoie, France, ENGIY operates in the power, natural gas, and energy services sectors. It functions through the Renewables, Networks, Energy Solutions, FlexGen, Retail, Nuclear, and Other segments.
On October 29, 2024, ENGIY and OCP Group announced a strategic partnership to accelerate OCP's energy transition in Morocco, focusing on renewable energy, energy storage, green hydrogen, and desalination.
The partnership includes developing four large-scale industrial projects and a research agenda, aiming to enhance competitiveness and support Morocco's ambitious energy goals.
On October 15, 2024, ENGIY announced the acquisition of its first biomethane production plant in Belgium, with a capacity of 68 GWh per year. This strategic purchase supports ENGIY's goal of producing 10 TWh of biomethane annually in Europe, enhancing its presence in the renewable energy sector.
In terms of the trailing-12-month Return on Total Capital, ENGIY's 6.82% is 69.8% higher than the 4.02% industry average. Likewise, its 15.94% trailing-12-month Return on Common Equity is 65.7% higher than the 9.62% industry average. Furthermore, the stock's 0.38x trailing-12-month asset turnover ratio is 75.2% higher than the 0.21x industry average.
ENGIY pays an annual dividend of $0.87, which translates to a yield of 5.15% at the current share price. Its four-year average dividend yield is 6.12%. Its dividend payouts have increased at a CAGR of 45.5% over the past three years.
For the first half ended June 30, 2024, ENGIY's revenues were €37.53 billion ($40.77 billion). Its cash flow from operating activities came in at €8.97 billion ($9.74 billion). Moreover, the company's net income and EPS were €2.40 billion ($2.61 billion) and €0.78, respectively, compared to a net loss of €217 million ($235.73 million) and a loss per share of $0.37.
For the quarter ended September 30, 2024, ENGIY's revenue is expected to increase marginally year-over-year to $16.15 billion. Over the past three months, the stock has gained 7.2% to close the last trading session at $16.84. Its 60-month beta is 0.94.
ENGIY's robust fundamentals are reflected in its POWR Ratings. It has an overall rating of A, equating to a Strong Buy in our proprietary rating system.
ENGIY has an A grade for Growth and a B grade for Value, Momentum, Stability, and Sentiment. Within the B-rated <a href="https://stocknews.com/category/utilities-foreign/">Utilities – Foreign</a> industry, it is ranked #5 out of 51 stocks. To see ENGIY's rating for Quality, <a href="https://stocknews.com/stock/ENGIY/">click here</a>.
Fortis Inc. (<a href="https://stocknews.com/stock/FTS/">FTS</a>)
Headquartered in St. John's, Canada, FTS operates as an electric and gas utility company in Canada, the United States, and the Caribbean. It generates, transmits, and distributes electricity to southeastern Arizona and in Arizona's Mohave and Santa Cruz counties, with an aggregate capacity of 3,408 megawatts (MW), including 68 MW of solar capacity and 250 MW of wind capacity.
In terms of the trailing-12-month EBIT margin, FTS' 28.79% is 35.3% higher than the 21.28% industry average. Likewise, its 44.98% trailing-12-month EBITDA margin is 23% higher than the 36.58% industry average. Furthermore, the stock's 37.54% trailing-12-month Capex / Sales is 11.2% higher than the 33.77% industry average.
FTS' annualized dividend of $1.77 per share translates to a dividend yield of 4.09% on the current share price. Its four-year average yield is 3.85%. Over the past five years, FTS' dividend payments have grown at a CAGR of 5.1%. The company has paid dividends for the past eight years.
During the second quarter that ended June 30, 2024, adjusted net earnings increased 9.6% over the prior-year quarter to C$331 million ($237.8 million). Similarly, the company's adjusted net earnings per share came in at $0.67, up 8.1% from the year-ago value.
Analysts expect FTS' revenue for the quarter ended September 30, 2024, to increase 8.9% year-over-year to $2.13 billion. Its EPS for the quarter ending December 31, 2024, is expected to increase 11.7% year-over-year to $0.60. FTS surpassed the consensus EPS estimates in each of the trailing four quarters.
Over the past six months, the stock has gained 10% to close the last trading session at $43.23. Its 24-month beta is 0.37.
FTS' positive outlook is reflected in its POWR Ratings. It has a B grade for Momentum and Stability. It is ranked #43 in the Utilities - Foreign industry. <a href="https://stocknews.com/stock/FTS/">Click here</a> to see FTS' ratings for Growth, Value, Sentiment, and Quality.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt;</a>

<hr />
DUK shares were trading at $112.68 per share on Friday afternoon, down $2.59 (-2.25%). Year-to-date, DUK has gained 19.71%, versus a 21.27% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Abhishek Bhuyan</h2> <img src='https:/wp-content/uploads/2023/07/ABhuyan.jpg' style="float:left; padding:5px;width:125px;">Abhishek embarked on his professional journey as a financial journalist due to his keen interest in discerning the fundamental factors that influence the future performance of financial instruments.<a href="https://stocknews.com/authors/?author=abhishek-bhuyan">More...</a>The post <a href=https://stocknews.com/news/duk-engiy-fts-3-utility-stocks-for-stability-and-dividend-growth/>3 Utility Stocks for Stability and Dividend Growth</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

Comments

Fortis

Notizie

Ultime notizie per Fortis (NYSE:FTS) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO